全文获取类型
收费全文 | 2427988篇 |
免费 | 180714篇 |
国内免费 | 5379篇 |
专业分类
耳鼻咽喉 | 32049篇 |
儿科学 | 81224篇 |
妇产科学 | 67082篇 |
基础医学 | 347482篇 |
口腔科学 | 70286篇 |
临床医学 | 219696篇 |
内科学 | 471426篇 |
皮肤病学 | 55130篇 |
神经病学 | 190239篇 |
特种医学 | 92101篇 |
外国民族医学 | 526篇 |
外科学 | 366847篇 |
综合类 | 56863篇 |
现状与发展 | 4篇 |
一般理论 | 869篇 |
预防医学 | 184392篇 |
眼科学 | 57625篇 |
药学 | 177121篇 |
9篇 | |
中国医学 | 5779篇 |
肿瘤学 | 137331篇 |
出版年
2019年 | 18761篇 |
2018年 | 27269篇 |
2017年 | 20790篇 |
2016年 | 23021篇 |
2015年 | 26178篇 |
2014年 | 36262篇 |
2013年 | 53944篇 |
2012年 | 73449篇 |
2011年 | 77760篇 |
2010年 | 46164篇 |
2009年 | 43238篇 |
2008年 | 72445篇 |
2007年 | 77140篇 |
2006年 | 77837篇 |
2005年 | 74599篇 |
2004年 | 72383篇 |
2003年 | 68926篇 |
2002年 | 66582篇 |
2001年 | 122096篇 |
2000年 | 125022篇 |
1999年 | 103987篇 |
1998年 | 27937篇 |
1997年 | 24682篇 |
1996年 | 24712篇 |
1995年 | 23712篇 |
1994年 | 21827篇 |
1993年 | 20263篇 |
1992年 | 80060篇 |
1991年 | 77626篇 |
1990年 | 75220篇 |
1989年 | 72461篇 |
1988年 | 65846篇 |
1987年 | 64955篇 |
1986年 | 61076篇 |
1985年 | 58260篇 |
1984年 | 43067篇 |
1983年 | 36524篇 |
1982年 | 21067篇 |
1981年 | 18860篇 |
1979年 | 38589篇 |
1978年 | 27149篇 |
1977年 | 23126篇 |
1976年 | 21597篇 |
1975年 | 22710篇 |
1974年 | 27550篇 |
1973年 | 26496篇 |
1972年 | 24520篇 |
1971年 | 22701篇 |
1970年 | 21117篇 |
1969年 | 19763篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
13.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
14.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
15.
16.
Clinical & Experimental Metastasis - 相似文献
17.
18.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
19.
20.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献